| Withdrawn | Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Precursor Cell Lymphoblastic Leukemia-lymphoma | Phase 1 | 2020-10-31 |
| Completed | A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Sev Hepatic Impairment, Healthy Volunteers | Phase 1 | 2020-10-09 |
| Completed | Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics ( Healthy Volunteers | Phase 1 | 2020-07-30 |
| Completed | A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys Renal Impairment, Healthy Volunteers | Phase 1 | 2020-03-04 |
| Completed | A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia Idiopathic Hypersomnia | Phase 1 | 2020-01-26 |
| Completed | Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung, Lung Neoplasms | Phase 1 | 2019-12-23 |
| Completed | Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sle Obstructive Sleep Apnea | Phase 1 | 2019-11-21 |
| Completed | A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Healthy Volunteers | Phase 1 | 2019-10-15 |
| Completed | Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS) Complex Regional Pain Syndrome | Phase 2 | 2019-07-23 |
| Completed | A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participa Healthy Volunteers | Phase 1 | 2019-05-02 |
| Completed | A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modificati Neoplasms, Advanced Solid | Phase 1 | 2019-03-28 |
| Completed | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Volunteers | Phase 1 | 2019-03-08 |
| Completed | A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics ( Healthy Volunteers | Phase 1 | 2019-02-27 |
| Completed | Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoin Hematopoietic Stem Cells | Phase 3 | 2019-02-06 |
| Completed | Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Multiple Myeloma | Phase 3 | 2019-01-24 |
| Completed | A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, P Healthy Volunteers | Phase 1 | 2019-01-22 |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination Wit Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic | Phase 1 | 2018-11-26 |
| Completed | A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Di Diabetic Gastroparesis, Idiopathic Gastroparesis | Phase 2 | 2018-10-14 |
| Terminated | TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) Critical Illness, Enteral Nutrition, Enteral Feeding Intolerance | Phase 2 | 2018-08-25 |
| Completed | A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Adva Advanced Solid Neoplasm | Phase 1 | 2018-08-13 |
| Completed | A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease Digestive System Disease | Phase 1 | 2018-06-19 |
| Terminated | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and M Healthy Volunteers | Phase 1 | 2018-05-30 |
| Completed | A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Mi Healthy Volunteers | Phase 1 | 2018-04-30 |
| Terminated | A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (G Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | Phase 1 | 2018-04-23 |
| Completed | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Adm Relapsed/Refractory, Multiple Myeloma | Phase 1 / Phase 2 | 2018-04-20 |
| Completed | A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of th Healthy Volunteers | Phase 1 | 2018-03-28 |
| Withdrawn | Efficacy and Safety of TAK-653 in Treatment-Resistant Depression Treatment-Resistant Depression | Phase 2 | 2018-02-15 |
| Completed | A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanc Advanced Solid Neoplasm | Phase 1 | 2017-11-15 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreat Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms | Phase 2 | 2017-10-25 |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants Wi Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis | Phase 2 | 2017-09-26 |
| Completed | A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma Relapsed and/or Refractory Multiple Myeloma | Phase 2 | 2017-08-01 |
| Completed | A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK Healthy Participants | Phase 1 | 2017-06-05 |
| Completed | A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors Advanced Solid Tumors, Neoplasms, Advanced Solid | Phase 1 | 2017-05-11 |
| Terminated | A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Dis Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 | 2017-04-28 |
| Terminated | A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib fo Lymphoma, Non-Hodgkin | Phase 1 | 2017-03-05 |
| Completed | MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-cell Metastatic Renal Cell Carcinoma | Phase 2 | 2016-06-30 |
| Terminated | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination Melanoma | Phase 1 | 2016-06-22 |
| Completed | A Study of Pevonedistat in Adult East Asian Participants Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1 | 2016-05-16 |
| Completed | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute | Phase 2 | 2016-04-14 |
| Completed | A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib Endometrial Neoplasms | Phase 2 | 2016-04-01 |
| Completed | A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors Nonhematologic Neoplasms, Advanced | Phase 1 | 2016-03-24 |
| Completed | A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modifica Neoplasm, Advanced or Metastatic | Phase 1 | 2016-01-08 |
| Terminated | MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Partic Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | Phase 1 | 2015-10-15 |
| Terminated | Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2015-06-03 |
| Completed | A Phase I Study of MLN6907 in Patients With Metastatic Colorectal Imaging of Solid Gastrointestinal Tumors | Phase 1 | 2015-06-01 |
| Completed | A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclit Non-hematologic Malignancy | Phase 1 | 2015-03-26 |
| Terminated | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors Advanced Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer | Phase 1 | 2015-03-19 |
| Completed | A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Advanced Nonhematologic Malignancies | Phase 1 | 2015-01-14 |
| Terminated | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Rec Advanced Gastrointestinal Carcinoma, Gastroesophageal Junction Adenocarcinoma, Recurrent Gastric Adenocarcinoma | Phase 1 | 2014-12-01 |
| Completed | A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advan Advanced Solid Tumors, Relapsed/Refractory Lymphoma | Phase 1 | 2014-10-22 |
| Completed | Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varyin Advanced Solid Tumors, Relapsed/Refractory Lymphoma | Phase 1 | 2014-08-21 |
| Terminated | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction Adenocarcinoma of the Stomach, Gastroesophageal Junction Expressing Guanylyl Cyclase C | Phase 2 | 2014-08-04 |
| Terminated | A Study of MLN0264 in Patients With Pancreatic Cancer Pancreatic Adenocarcinoma | Phase 2 | 2014-07-02 |
| Completed | Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer Prostate Cancer | Phase 2 | 2014-06-01 |
| Completed | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclita Small Cell Lung Cancer | Phase 2 | 2014-05-12 |
| Completed | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerab Advanced Solid Tumors | Phase 1 | 2014-04-01 |
| Completed | A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Coho Prostate Cancer | Phase 2 | 2014-03-26 |
| Completed | Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB Advanced Solid Tumors, Lymphoma | Phase 1 | 2014-03-19 |
| Completed | A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Hodgkin Lymphoma | Phase 4 | 2014-03-14 |
| Completed | Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone i Multiple Myeloma | Phase 2 | 2014-03-05 |
| Completed | A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Prostate Cancer, Endometriosis | Phase 1 | 2014-03-01 |
| Terminated | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors Advanced Malignant Solid Tumors | Phase 1 | 2014-01-31 |
| Completed | A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lym Hodgkin Lymphoma, Anaplastic Large-cell Lymphoma | Phase 1 | 2013-11-01 |
| Completed | Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma Follicular Lymphoma | Phase 2 | 2013-10-31 |
| Completed | Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid T Multiple Myeloma, Advanced Solid Tumors | Phase 1 | 2013-09-16 |
| Withdrawn | Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies Advanced Nonhematologic Malignancies | Phase 1 | 2013-08-01 |
| Completed | Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction Advanced Solid Tumors, Hematologic Malignancies | Phase 1 | 2013-08-01 |
| Completed | Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas Advanced Solid Tumors, Lymphoma | Phase 1 | 2013-07-16 |
| Completed | A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Advanced Nonhematologic Malignancies | Phase 1 | 2013-06-28 |
| Completed | Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single Solid Tumors, Lymphoma | Phase 1 | 2013-06-25 |
| Completed | Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Pac Solid Tumors | Phase 1 | 2013-06-10 |
| Completed | IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patie Multiple Myeloma | Phase 3 | 2013-04-29 |
| Completed | Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Ar Acute Myelogenous Leukemia | Phase 1 | 2013-04-10 |
| Completed | Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib Advanced Solid Tumors, Lymphoma | Phase 1 | 2013-01-24 |
| Terminated | Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Sys Relapsed or Refractory Systemic Light Chain Amyloidosis | Phase 3 | 2012-12-26 |
| Completed | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants Multiple Myeloma | Phase 1 | 2012-12-17 |
| Completed | Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK Prostate Cancer | Phase 1 / Phase 2 | 2012-08-20 |
| Completed | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Parti Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma | Phase 3 | 2012-06-11 |
| Completed | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | Phase 3 | 2012-06-11 |
| Completed | Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyc Advanced Gastrointestinal Malignancies | Phase 1 | 2012-06-01 |
| Completed | Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Re Prostate Cancer | Phase 2 | 2012-05-01 |
| Completed | Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Ana Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma | Phase 1 / Phase 2 | 2012-04-16 |
| Completed | A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas Advanced Solid Tumors, Lymphomas | Phase 1 | 2012-02-06 |
| Terminated | Surveillance Study of Patients With Newly Diagnosed Osteosarcoma Osteosarcoma | — | 2011-12-01 |
| Completed | Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma Nonhematologic Malignancies, Lymphoma | Phase 1 | 2011-11-10 |
| Completed | Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma | Phase 1 / Phase 2 | 2011-10-31 |
| Completed | Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer Metastatic Solid Tumors | Phase 1 | 2011-10-01 |
| Completed | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Part Melanoma, Metastatic Melanoma, Solid Tumor | Phase 1 | 2011-09-15 |
| Completed | Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab Inflammatory Bowel Disease | Phase 1 | 2011-09-01 |
| Completed | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincrist Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma | Phase 1 / Phase 2 | 2011-08-09 |
| Completed | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multi Multiple Myeloma | Phase 1 / Phase 2 | 2011-06-27 |
| Completed | Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis Light-Chain Amyloidosis | Phase 1 | 2011-04-27 |
| Completed | Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Ad Advanced Solid Malignancies, Hematologic Malignancies | Phase 1 | 2011-02-28 |
| Completed | A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Multiple Myeloma | Phase 1 / Phase 2 | 2010-11-22 |
| Completed | Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer Prostate Cancer | Phase 3 | 2010-11-15 |
| Completed | Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease Crohn's Disease | Phase 3 | 2010-11-01 |
| Terminated | Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of Prostate Cancer, Prostatic Neoplasms | Phase 1 / Phase 2 | 2010-11-01 |
| Completed | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia Relapsed Multiple Myeloma, Refractory Multiple Myeloma, Waldenstrom Macroglobulinemia | Phase 1 | 2010-11-01 |
| Completed | Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resist Prostate Cancer | Phase 3 | 2010-10-01 |
| Completed | A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies Advanced Nonhematologic Malignancies, Carcinoma, Basal Cell | Phase 1 | 2010-10-01 |
| Terminated | Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies Advanced Nonhematological Malignancies | Phase 1 | 2010-09-01 |
| Completed | A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate C Advanced Solid Tumors, Adenocarcinoma of the Prostate | Phase 1 | 2010-08-17 |
| Completed | Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Pros Prostate Cancer | Phase 1 / Phase 2 | 2010-07-01 |
| Completed | Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Prostate Cancer | Phase 2 | 2010-05-01 |
| Completed | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Stud Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer | Phase 2 | 2010-04-16 |
| Completed | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck o Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | 2010-02-01 |
| Completed | Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies Advanced Solid Malignancies | Phase 1 | 2010-01-04 |
| Completed | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cy Diffuse Large B-Cell Lymphoma | Phase 2 | 2010-01-01 |
| Completed | Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies Advanced Non-hematologic Malignancies, Advanced Metastatic Melanoma | Phase 1 | 2009-12-01 |
| Completed | Dose Escalation Study of MLN4924 in Adults With Melanoma Metastatic Melanoma | Phase 1 | 2009-12-01 |
| Completed | Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma Relapsed and Refractory Multiple Myeloma | Phase 1 | 2009-10-12 |
| Completed | Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma Advanced Solid Tumors, Lymphoma | Phase 1 | 2009-10-01 |
| Completed | Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed Multiple Myeloma | Phase 1 | 2009-10-01 |
| Completed | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | 2009-10-01 |
| Completed | Study of MLN8237 in Participants With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2009-09-25 |
| Terminated | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma P Follicular Lymphoma | Phase 2 | 2009-09-01 |
| Completed | A Study of IXAZOMIB in Adult Patients With Lymphoma Lymphoma | Phase 1 | 2009-08-01 |
| Completed | MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leu Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome | Phase 1 | 2009-06-01 |
| Withdrawn | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomi Glioblastoma Multiforme | Phase 1 | 2009-06-01 |
| Completed | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma Ovarian Carcinoma | Phase 2 | 2009-03-23 |
| Completed | A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies Advanced Non-hematologic Malignancies | Phase 1 | 2009-03-02 |
| Completed | Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies Advanced Solid Tumors | Phase 1 | 2009-03-01 |
| Completed | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia | Phase 1 | 2009-03-01 |
| Completed | A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplasti Acute Myelogenous Leukemia, High-Grade Myelodysplastic Syndrome | Phase 2 | 2009-02-10 |
| Completed | Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma | Phase 2 | 2009-02-10 |
| Completed | Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis Ulcerative Colitis | Phase 3 | 2009-01-01 |
| Completed | Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer Solid Tumors | Phase 1 | 2009-01-01 |
| Completed | Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease Crohn's Disease | Phase 3 | 2008-12-01 |
| Completed | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma Relapsed Follicular Lymphoma | Phase 2 | 2008-09-01 |
| Completed | Study of MLN8237 in Participants With Advanced Hematological Malignancies B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | 2008-07-11 |
| Completed | A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma Multiple Myeloma | Phase 3 | 2008-07-01 |
| Completed | Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple My Hematologic Malignancies, Multiple Myeloma, Lymphoma | Phase 1 | 2008-06-01 |
| Completed | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cy Mantle Cell Lymphoma | Phase 3 | 2008-05-01 |
| Completed | Study of MLN4924 in Adult Patients With Nonhematologic Malignancies Advanced Nonhematologic Malignancies | Phase 1 | 2008-04-01 |
| Completed | Safety Study of TAK-700 in Subjects With Prostate Cancer. Prostatic Neoplasms | Phase 1 / Phase 2 | 2008-04-01 |
| Completed | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relap Follicular Lymphoma | Phase 2 | 2008-02-01 |
| Completed | Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma Osteosarcoma | — | 2008-01-01 |
| Completed | Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease Ulcerative Colitis, Crohn's Disease | Phase 2 | 2007-12-01 |
| Completed | A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants Wi Advanced Malignancies | Phase 1 | 2007-10-22 |
| Completed | A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclo Multiple Myeloma | Phase 2 | 2007-10-01 |
| Completed | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) Multiple Myeloma, Non-Hodgkin's Lymphoma | Phase 1 | 2007-09-01 |
| Completed | A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer Cancer | Phase 1 | 2007-08-01 |
| Completed | Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Pat Multiple Myeloma | Phase 1 / Phase 2 | 2007-08-01 |
| Completed | Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednis Multiple Myeloma | Phase 3 | 2007-06-01 |
| Completed | A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors Advanced Malignancies | Phase 1 | 2007-05-15 |
| Completed | Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis Ulcerative Colitis | Phase 2 | 2007-05-01 |
| Withdrawn | Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing R Ovarian Cancer | Phase 2 | 2006-07-01 |
| Terminated | A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies Advanced Malignancies | Phase 1 | 2006-04-01 |
| Completed | Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Non-Hodgkin's Lymphoma | Phase 3 | 2006-03-01 |
| Terminated | A Study of MLN8054 in Patients With Advanced Solid Tumors Breast Neoplasm, Colon Neoplasm, Pancreatic Neoplasm | Phase 1 | 2005-10-01 |
| Terminated | A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer NSCLC | Phase 2 | 2005-08-01 |
| Completed | Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Ri Atherosclerosis | Phase 2 | 2005-08-01 |
| Completed | Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis Amyloidosis | Phase 1 / Phase 2 | 2005-06-01 |
| Completed | Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis Multiple Sclerosis | Phase 2 | 2005-05-01 |
| Terminated | VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarc Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Bronchiolo-Alveolar | Phase 2 | 2005-04-01 |
| Completed | MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myel Acute Myelogenous Leukemia | Phase 1 | 2005-03-01 |
| Completed | VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myelom Multiple Myeloma | Phase 3 | 2004-12-01 |
| Completed | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma B-Cell Lymphoma, Follicular Lymphoma, Marginal Lymphoma | Phase 2 | 2004-05-01 |
| Completed | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma Multiple Myeloma | Phase 1 | 2004-03-01 |
| Completed | MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer Prostatic Neoplasms | Phase 1 / Phase 2 | 2003-10-01 |
| Completed | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Mantle Cell Lymphoma | Phase 2 | 2003-06-01 |
| Completed | PROTECT-TIMI 30 Trial Unstable Angina | Phase 3 | 2003-05-01 |
| Terminated | Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer o Advanced Non-Small Cell Lung Cancer, Other Solid Tumors | Phase 1 | 2002-12-01 |
| Completed | Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Colorectal Carcinoma | Phase 2 | 2002-12-01 |
| Completed | Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Pros Prostatic Neoplasms | Phase 1 / Phase 2 | 2002-12-01 |
| Completed | Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Sma Non-Small Cell Lung Cancer | Phase 2 | 2002-12-01 |
| Completed | A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer Prostate Cancer | Phase 1 | 2002-11-01 |
| Completed | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Multiple Myeloma | Phase 3 | 2002-06-01 |
| Completed | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 | 2002-05-01 |
| Completed | A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Multiple Myeloma | Phase 3 | 2002-04-01 |
| Completed | Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients Crohn's Disease | Phase 2 | 2000-02-01 |
| Completed | Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Tumors, Non-Hodgkins's Lymphoma | Phase 1 | — |
| No Longer Available | A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE Multiple Myeloma | — | — |
| Completed | Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When U Tumors | Phase 1 | — |
| Withdrawn | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered I Acute Myelogenous Leukemia | Phase 1 / Phase 2 | — |
| Completed | Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Loc Non-Small Cell Lung Cancer | Phase 2 | — |
| Completed | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Multiple Myeloma | Phase 4 | — |
| Approved For Marketing | An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants Wit Carcinoma, Non-Small-Cell Lung | — | — |